Fran Schulz - 25 Jun 2025 Form 4 Insider Report for Senti Biosciences, Inc. (SNTI)

Reporting relationship: Director
Issuer ticker: SNTI
Reported as of: 25 Jun 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 27 Jun 2025, 19:53:44 UTC
Prior SEC filing: 11 Mar 2025
Next SEC filing: 09 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ Robert Cutler, attorney-in-fact

Key filing fact

Fran Schulz filed Form 4 for Senti Biosciences, Inc. (SNTI) on 27 Jun 2025.

Key facts

This page summarizes Fran Schulz's Form 4 filing for Senti Biosciences, Inc. (SNTI).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 27 Jun 2025, 19:53.

Change

Previous filing in this sequence was filed on 11 Mar 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002046804 Primary reporting owner

Schulz Fran

Relationship: Director
Address: C/O SENTI BIOSCIENCES, INC., 2 CORPORATE DRIVE FIRST FLOOR, SOUTH SAN FRANCISCO
Signature: /s/ Robert Cutler, attorney-in-fact
Signature date: 27 Jun 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SNTI transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +21,950
Change %
Price: $0.000000
Shares after: 21,950
Date: 25 Jun 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 21,950
Exercise price: $2.05
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

100% of the shares underlying this option vest upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the 2026 Annual Meeting, subject to the reporting person's continued service through the applicable vesting date.